Newsroom

11

February 2020

Tuesday

iX Biopharma Ltd. has reported results for the second quarter and/or half yearly results as of 31 December 2019.

The second quarter financial statements for the period can be found here.

30

January 2020

Thursday

iX Biopharma Ltd has published its presentation for Phillip securities Jan 2020.

The presentation can be found here.

10

December 2019

Tuesday

iX Biopharma Ltd is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublingual ketamine wafer for the treatment of acute moderate to severe pain.

More information can be found in the attached press release.

05

December 2019

Thursday

iX Biopharma Ltd is pleased to announce that it has been granted a cannabis manufacturing licence from the Office of Drug Control in Australia.

The Group has now secured all the necessary licences for its Australian TGA cGMP facility to manufacture, import and export medicinal cannabis.

More information can be found in the attached press release.

 

05

November 2019

Tuesday

iX Biopharma Ltd. has reported results for the first quarter and financial year ended 30 September 2019.

The first quarter financial statements for the period can be found here.

22

October 2019

Tuesday

iX Biopharma Ltd is pleased to announce that it has been granted a patent in India (Patent no. 319759) for its WaferiX™ drug delivery technology.

More information can be found in the attached press release.

18

October 2019

Friday

iX Biopharma Ltd is pleased to announce that at the Annual General Meeting of the Company held on 18 October 2019, all resolutions set out in the Notice of AGM dated 26 September 2019 were duly passed by way of poll vote.

The results of the Annual General Meeting can be found here.

26

September 2019

Thursday

iX Biopharma Ltd has published its Annual Report for FY2019.

The Annual Report can be found here, together with the Notice of AGM.

06

September 2019

Friday

iX Biopharma Ltd participated in SGX’s 20th anniversary celebrations by striking the SGX gong to open the Singapore securities market on 6 September 2019. The Company commemorated its milestones since listing and shared about its growth drivers and market trends impacting the healthcare industry.

Read On

23

August 2019

Friday

iX Biopharma Ltd. has reported results for the fourth financial quarter and financial year ended 30 june 2019

The fourth quarter financial statements for the period can be found here.

For all company announcements, please refer to SGX company disclosures page.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com